LONDON, UK: Renalytix AI plc, a developer of artificial intelligence-enabled diagnostics for kidney disease, announced the expansion of its leadership team with the appointment of diagnostic industry leader Thomas McLain as President and Chief Commercial Officer, effective immediately.

In this non-Board role, McLain will be responsible for leading the commercial programme for KidneyIntelX™ with a focus on establishing national and international clinical adoption and reimbursement.

McLain most recently led business and commercial strategy for the Exosome Diagnostics’ ExosomeDx® Prostate (Intelliscore) (EPI) test, a liquid biopsy diagnostic for identifying men at increased risk for aggressive or high grade prostate cancer.

McLain has been recognised as a leading voice for progressive diagnostic reimbursement strategy including innovative collaborations and programmes with private insurance groups to stimulate utility, outcome and health economic data collection leading to accelerated clinical adoption and positive coverage determinations.

McLain has served as President, Chief Executive Officer (CEO), General Manager, Board Chair and Board member of numerous successful pharmaceutical, biotechnology and diagnostic companies.

James McCullough, Chief Executive Officer, RenalytixAI commented: “I am honoured to welcome Tom to the RenalytixAI leadership team. Tom’s deep understanding of diagnostic product commercialisation, healthcare markets and reimbursement will be a great asset to our company.”